Massachusetts Financial Services Co. MA Takes $242,000 Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Massachusetts Financial Services Co. MA bought a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 23,662 shares of the company’s stock, valued at approximately $242,000. Massachusetts Financial Services Co. MA owned 0.06% of iTeos Therapeutics at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in iTeos Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company’s stock valued at $20,468,000 after buying an additional 9,660 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in iTeos Therapeutics by 14.8% in the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock valued at $13,481,000 after purchasing an additional 117,159 shares during the last quarter. Candriam S.C.A. acquired a new stake in iTeos Therapeutics during the 2nd quarter valued at approximately $7,558,000. Clearline Capital LP acquired a new stake in iTeos Therapeutics during the 2nd quarter valued at approximately $2,328,000. Finally, Kennedy Capital Management LLC purchased a new stake in iTeos Therapeutics during the 1st quarter worth approximately $1,988,000. 97.16% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on ITOS shares. HC Wainwright reiterated a “buy” rating and set a $46.00 target price on shares of iTeos Therapeutics in a research note on Friday, November 15th. Wedbush reiterated an “outperform” rating and set a $25.00 price objective on shares of iTeos Therapeutics in a research note on Tuesday, November 12th. JPMorgan Chase & Co. dropped their target price on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research report on Monday, August 12th. Finally, Wells Fargo & Company initiated coverage on shares of iTeos Therapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price target on the stock.

Insider Activity

In other news, CFO Matthew Gall purchased 5,000 shares of iTeos Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $7.73 per share, with a total value of $38,650.00. Following the completion of the acquisition, the chief financial officer now owns 65,429 shares in the company, valued at $505,766.17. The trade was a 8.27 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 12.50% of the company’s stock.

iTeos Therapeutics Price Performance

iTeos Therapeutics stock opened at $8.54 on Thursday. iTeos Therapeutics, Inc. has a 12 month low of $7.54 and a 12 month high of $18.75. The company has a fifty day moving average price of $9.23 and a two-hundred day moving average price of $13.74. The company has a market cap of $312.00 million, a PE ratio of -2.71 and a beta of 1.39.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.18) by $0.13. Equities research analysts anticipate that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current year.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.